BioSpace News Archive

Lonza (SIX: LONN), a global development and manufacturing partner to the pharma, biotech and nutrition industries, and NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a company developing treatments for amyotrophic lateral sclerosis (ALS) and other severe neurodegenerative diseases.

HeartBeam, Inc. (NASDAQ: BEAT) today announced new data demonstrating that applying the company’s artificial intelligence (AI) algorithms to vectorcardiography (VCG) showed considerably improved performance in the detection of atrial flutter over single-lead electrocardiograms (ECGs) and similar performance to 12-lead ECGs, the standard for diagnosing atrial flutter.

Epic Bio, a leading epigenetic editing company that plans to have its FSHD program enter the clinic this year, today announced the acceptance of six abstracts, three oral presentations, and three poster presentations at the upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT), taking place May 7-11, 2024, in Baltimore, Maryland.

HealthTrackRx, the nation’s premier molecular diagnostic testing laboratory, announced the appointment of Steven Goldberg, MD, MBA, as its Chief Medical Officer.

C2Sense, Inc., experts in advanced optical sensing platforms and Princeton BioMeditech Corporation, a world leader in rapid, point-of-care diagnostics, announced that they have secured a second National Institutes of Health Rapid Acceleration of Diagnostics Tech High Performance award.

Hackensack Meridian Hackensack University Medical Center, a center of excellence and an international leader in robotic-assisted surgery, was selected to be one of only 14 centers in the world, and the only in New Jersey, New York and Connecticut, to acquire the Intuitive Surgical da Vinci 5 multiport surgical system.

BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) (“BioMark” or the “Company”) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today

According to Nova One Advisor, the global biomarkers market size was exhibited at USD 81.19 billion in 2023 and is projected to hit around USD 284.76 billion by 2033, growing at a CAGR of 13.37% during the forecast period 2024 to 2033.

BioCity Biopharma today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for a Phase 1 study of BC2027.

Transcat Inc. announced that Mark Doheny will step down as Chief Operating Officer of Transcat effective immediately.